Abstract
Legionella is a potential causative pathogen in pneumonia. It is also a facultative intracellular bac terium and, because it multiplies in macrophages, results of in vitro susceptibility tests do not always reflect clinical therapeutic effect. For this reason, it is necessary to test for both intracellular penetra tion of the agent and bactericidal activity against intracellular multiplying Legionella. In this study, the antibacterial activity of sparfloxacin, a newly developed fluoroquinolone, against Legionella was studied and compared with that of ofloxacin, ciprofloxacin, norfloxacin, and erythromycin. 1. Materials and Methods The minimum inhibitory concentrations (MICs) for the Legionella species were determined by the micro dilution broth method. A total of 68 Legionella strains were used in this study: standard reference strains of L. pneumophila (serogroups 1 to 13, n = 14) and Legionella spp. (n = 27); and clinical isolates of L. pneumophila (serogroup 1, n = 21; serogroup 2, n = 2; serogroup 3, n = 1; Table I. Minimum inhibitory concentration (MIG) of 5 antibacterial
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
